Industry Members in the News
Funding from Ontario government launches
OmniaBio Inc.
OmniaBio Inc’s new facility will be the largest CDMO in Canada for the manufacture of CGTs
March 31, 2022 (Toronto, ON) – OmniaBio Inc., a subsidiary of CCRM, is the first project to be funded under the Invest Ontario Fund. Subject to reaching a definitive agreement, OmniaBio Inc. will be the recipient of a loan of up to $40 million from the Government of Ontario, funding that will kickstart the construction of a 250,000 ft2 (23,225 m2) contract development and manufacturing organization (CDMO) for cell and gene therapies (CGTs) – the largest facility of its kind in Canada.
Read the Full Release Here
This press release was written and distributed by CCRM
For all enquires, please contact CCRM directly
#IndustryMemberNews#29.7